Market Overview

The Global Duchenne Muscular Dystrophy Treatment Market was valued at USD 3,561.9 million in 2023 and is expected to reach USD 8,882.2 million by 2031 while growing at a CAGR of 12.1% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global Duchenne Muscular Dystrophy Treatment market growth. Duchenne muscular dystrophy (DMD) is a genetic disorder marked by progressive muscle degeneration and weakness, with no current cure. However, various treatment strategies focus on symptom management, disease progression deceleration, and enhancing quality of life.

Ongoing research efforts focused on understanding the mechanisms of DMD and developing new therapies, along with increased investment in orphan drug development, propel the Duchenne muscular dystrophy (DMD) treatment market. Yet, the market growth faces obstacles such as the high cost of therapy and concerns regarding safety and efficacy.

Furthermore, the global Duchenne Muscular Dystrophy Treatment industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Therapeutic Approaches Analysis

The Global Duchenne Muscular Dystrophy Treatment Market is segmented among Molecular-based Therapies, Corticosteroids, and Other Therapeutic Approaches, based on Therapeutic Approaches. In 2023, Molecular-based Therapies accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Duchenne Muscular Dystrophy Treatment Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are BioMarin, Fibrogen Inc., Nobelpharma Co. Ltd, NS Pharma Inc., Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, F. Hoffmann-La Roche AG, and ReveraGen BioPharma.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Duchenne Muscular Dystrophy Treatment Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Duchenne Muscular Dystrophy Treatment Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Duchenne Muscular Dystrophy Treatment Market Segmentation, By Therapeutic Approaches

• Global Duchenne Muscular Dystrophy Treatment Market Share Analysis, By Therapeutic Approaches

• Global Duchenne Muscular Dystrophy Treatment Market Growth Analysis, By Therapeutic Approaches

• Global Duchenne Muscular Dystrophy Treatment Market Trends, By Therapeutic Approaches

o Molecular-based Therapies

Ø Mutation Suppression

Ø Exon Skipping

o Corticosteroids

o Other Therapeutic Approaches

6. Global Duchenne Muscular Dystrophy Treatment Market Segmentation, By Region

• Global Duchenne Muscular Dystrophy Treatment Market Share Analysis, By Region

• Global Duchenne Muscular Dystrophy Treatment Market Growth Analysis, By Region

• Global Duchenne Muscular Dystrophy Treatment Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• BioMarin*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Fibrogen Inc.

• Nobelpharma Co. Ltd

• NS Pharma Inc.

• Pfizer Inc.

• PTC Therapeutics

• Santhera Pharmaceuticals

• Sarepta Therapeutics

• F. Hoffmann-La Roche AG

• ReveraGen BioPharma  

*Similar analysis will be provided for each company listed above.